

ExonHit announces Highmark's decision to maintain coverage of PathFinderTG® - Pancreatic cancer test

- Coverage is contingent upon implementation of a database compiling the results of the first line tests performed on Medicare patients
- This coverage decision applies solely to PathFinderTG® – Pancreatic cancer test and not to other therapeutic indications of PathFinderTG®
- ExonHit and RedPath welcome this decision and are currently evaluating the impact of such coverage decision on the planned acquisition

Paris, France – September 21, 2010 – ExonHit Therapeutics (Alternext: ALEHT) today informs its shareholders that on September 20, 2010, Highmark decided to continue coverage of PathFinderTG® – Pancreatic cancer test as a “reasonable and necessary” service specifically and only for the indications of pancreatic cyst/mass where first line diagnostic evaluations are inconclusive, under “Coverage with Appropriateness Development” (CAD). As a requirement for this CAD, Medicare requests that RedPath maintain and populate a Medicare-specific database of all Medicare patients for which PathFinderTG® is utilized as a diagnostic tool. This information collection will begin no later than January 1, 2011 and will be provided to Medicare every six months.

“This decision is good news for both patients and physicians. It acknowledges the clinical utility of RedPath’s pancreatic cancer test as a second line test at times when standard pathologic analyses provide inconclusive information,” said Loïc Maurel M.D., President of ExonHit Therapeutics’ Management Board. “We will discuss together with RedPath in the coming days to evaluate the impact of this decision on the planned acquisition.”

Highmark’s coverage decision will apply to PathFinderTG® – Pancreatic cancer test services performed on or after November 5, 2010. All other indications contemplated for current or future RedPath products are considered investigational and therefore are not eligible for coverage.

The full text related to Highmark’s Local Coverage Decision, LCD L31144, dated September 20, 2010 can be found at <https://www.highmarkmedicare services.com/policy/mac-ab/l31144.html>.

About RedPath Integrated Pathology, Inc.

ExonHit Therapeutics announced on April 26, 2010 the signature of an agreement for the acquisition of RedPath Integrated Pathology, Inc., a privately held US molecular diagnostic company, focused on cancer. On June 16, 2010, RedPath informed ExonHit that Highmark, a Medicare reimbursement regional antenna, could in the near future discontinue coverage of PathFinderTG®, RedPath’s lead product, contingent upon a complementary assessment of the utility of the product. On July 8, 2010, RedPath submitted to Highmark a dossier supporting the clinical utility of PathFinderTG® test, seeking maintenance of coverage.

About the US healthcare system

Medicare is a social insurance program administered by the United States government, providing health insurance coverage to people who are aged 65 and over. *Medicaid* is the United States health program for eligible individuals and families with low incomes and resources. Medicare and Medicaid are administered by the US federal agency called *Centers for Medicare & Medicaid Services* or CMS.

From an operational standpoint, CMS contracts the management of its covered patients to regional organization such as Highmark, who is the regional contractor for the States of Delaware (DE), New Jersey (NJ), and Pennsylvania (PA).

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast-emerging healthcare player active in both therapeutics and diagnostics. The company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with in-house development programs and strategic collaborations, in particular with bioMérieux and Allergan).

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contact for Media & Investors

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com